Extended Data Fig. 9: ARF4TP-4 obviously prevents the body weight lost and histopathological changes after IAV challenge.
From: ARF4-mediated intracellular transport as a broad-spectrum antiviral target
ARF4TP-4 treatment and IAV challenge were performed as described in Fig. 6h. a) Body weight daily monitor was performed in both PBS and ARF4TP-4 treated mice (n = 8) for 14 days post IAV inoculation or till the body weight reduction was up to 25%. For group mean plots in b), weight loss is shown as mean ± SEM). c, d) H&E staining and histopathological score of IAV infected lung sections collected from PBS and ARF4TP-4 treated mice at 6 dpi. Each coloured plot in above panels represents a randomly picked mouse. Scale bar, 100 μM.
